



SENSITIVE INFORMATION – WITHHOLD UNDER 10 CFR 2.390(a)(4)

September 28, 2021

ULNRC-06694

U.S. Nuclear Regulatory Commission
Attn: Document Control Desk
Washington, DC 20555-0001

Ladies and Gentlemen:

10 CFR 2.390

**DOCKET NUMBER 50-483
CALLAWAY PLANT UNIT 1
UNION ELECTRIC CO.
RENEWED FACILITY OPERATING LICENSE NPF-30
PRESENTATION INFORMATION FOR SECOND PRE-APPLICATION MEETING
REGARDING USE OF FRAMATOME FUEL AT CALLAWAY PLANT**

Reference: 1. NRC letter dated July 1, 2021, "Summary of May 20, 2021, Partially Closed Pre-Application Teleconference with Union Electric Company Regarding Approval to Insert Framatome's GAIA Fuel Assemblies in Their Core in Reload Quantities for Callaway Plant, Unit No. 1 (EPID L-2021-LRM-0043)" (Access. No. ML21168A002)

In a meeting conducted with the NRC on May 20, 2021, Ameren Missouri presented information pertaining to the potential use of fuel from a new/different fuel vendor (Framatome) for the Callaway plant. It was noted in that meeting that four lead Framatome fuel assemblies have already been placed in the core in non-limiting locations and that a license amendment will be needed to load qualified fuel assemblies in greater quantities, including batch quantities in future refuel outages. The May 20, 2021 meeting, summarized per Reference 1, was therefore a pre-submittal meeting in support of the license amendment needed for the transition to Framatome fuel. The license amendment request is planned for submittal in 2022.

Subsequent to the Reference 1 meeting, some changes in the approach to the planned license amendment request were identified such that the need for a follow-up (second) pre-submittal meeting was recognized. A proposed follow-up meeting was discussed with the NRC, and a meeting date of October 14, 2021 for a second pre-submittal meeting has since been confirmed. Just like the May 20, 2021 meeting, a portion of the October 14 meeting is expected to be closed to public participation since some of the information to be presented is considered proprietary to Framatome. The presentation material to be used for the meeting has been prepared and is being provided via this letter.

Enclosure 3 to this letter contains sensitive information.
Withhold from public disclosure under 10 CFR 2.390(a)(4).
Upon removal of Enclosure 3, this letter is uncontrolled.

SENSITIVE INFORMATION – WITHHOLD UNDER 10 CFR 2.390(a)(4)

Similar to the May 20, 2021 meeting, the presentation materials to be used for the October 14, 2021 meeting are in the form of PowerPoint slides. One set of slides (non-proprietary) is provided per Enclosure 1 of this letter, which is to be used for the public meeting. Two sets of slides are provided in connection with the closed meeting. Specifically, the slides provided in Enclosure 2 are a redacted, non-proprietary version of the closed meeting slides, from which the proprietary information has been removed, as shown on the affected slides. Enclosure 3 provides the proprietary version of the closed meeting slides for use in the closed meeting. To be clear, Enclosure 3 contains information that is proprietary to Framatome and is to be withheld from public disclosure. For both Enclosures 2 and 3, brackets and notation indicate the placement of the proprietary information and the basis for withholding the information from public disclosure pursuant to 10 CFR 2.390. The basis for withholding is further explained in the Framatome affidavit provided as Enclosure 4.

This letter does not contain new commitments.

If there are any questions, please contact Tom Elwood at (314) 225-1905.

Sincerely,



Steve Meyer
Manager, Regulatory Affairs

DRB/mlp

Enclosures:

1. Callaway Unit 1 Presentation Information for Planned Pre-Application Meeting (Public Meeting)
2. Callaway Unit 1 Presentation Information for Planned Pre-Application Meeting (Closed Meeting), Non-Proprietary (Redacted) Version for Closed Meeting
3. Callaway Unit 1 Presentation Information for Planned Pre-Application Meeting (Closed Meeting), Proprietary (Non-Redacted) Version for Closed Meeting
4. Affidavit

<p>Enclosure 3 to this letter contains sensitive information. Withhold from public disclosure under 10 CFR 2.390(a)(4). Upon removal of Enclosure 3, this letter is uncontrolled.</p>

September 28, 2021

Page 3 of 4

cc: Mr. Scott A. Morris
 Regional Administrator
 U. S. Nuclear Regulatory Commission
 Region IV
 1600 East Lamar Boulevard
 Arlington, TX 76011-4511

Senior Resident Inspector
Callaway Resident Office
U.S. Nuclear Regulatory Commission
8201 NRC Road
Steedman, MO 65077

Mr. M. Chawla
Project Manager, Callaway Plant
Office of Nuclear Reactor Regulation
U. S. Nuclear Regulatory Commission
Mail Stop 08B1A
Washington, DC 20555-0001

<p>Enclosure 3 to this letter contains sensitive information. Withhold from public disclosure under 10 CFR 2.390(a)(4). Upon removal of Enclosure 3, this letter is uncontrolled.</p>

Index and send hardcopy to QA File A160.0761

Hardcopy:

Certrec Corporation
6500 West Freeway, Suite 400
Fort Worth, TX 76116
(w/o enclosure)

Electronic distribution for the following can be made via Responses and Reports ULNRC Distribution:

F. M. Diya
B. L. Cox
F. J. Bianco
S. P. Banker
S. J. Meyer
R. C. Wink
T. B. Elwood
L. D. Russell
R. J. Andreasen
B. D. Richardson
T. S. Gardner, Framatome
NSRB Secretary w/o enclosure
Mrs. Melissa Friel, REP Manager (SEMA) w/o enclosure
STARS Regulatory Affairs w/o enclosure
Mr. Jay Silberg (Pillsbury Winthrop Shaw Pittman LLP) w/o enclosure
Ms. Katie Jo Wheeler (DNR) w/o enclosure

<p>Enclosure 3 to this letter contains sensitive information. Withhold from public disclosure under 10 CFR 2.390(a)(4). Upon removal of Enclosure 3, this letter is uncontrolled.</p>
